You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZidovudine
Accession NumberDB00495  (APRD00449)
TypeSmall Molecule
GroupsApproved
DescriptionA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Structure
Thumb
Synonyms
Azidothymidine
AZT
ZDV
Zidovudin
Zidovudinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-azt Cap 100mgCapsule100 mgOralNovopharm Limited1992-12-312015-10-26Canada
RetrovirInjection, solution10 mg/mLIntravenousVii V Healthcare Company2010-11-04Not applicableUs
RetrovirCapsule100 mg/1OralVii V Healthcare Company2010-10-28Not applicableUs
RetrovirSyrup10 mg/mLOralVii V Healthcare Company2010-10-28Not applicableUs
Retrovir (azt)Capsule100 mgOralViiv Healthcare Ulc1990-12-31Not applicableCanada
Retrovir (azt)Liquid10 mgIntravenousViiv Healthcare Ulc1991-12-31Not applicableCanada
Retrovir (azt)Syrup50 mgOralViiv Healthcare Ulc1991-12-31Not applicableCanada
Retrovir (azt) 300mgTablet300 mgOralGlaxo Wellcome Inc.1998-09-232000-11-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-zidovudineCapsule100 mgOralApotex Inc1992-12-31Not applicableCanada
Lamivudine and ZidovudineTablet, film coated150 mg/1OralREMEDYREPACK INC.2013-04-112016-10-13Us
ZidovudineTablet300 mg/1OralREMEDYREPACK INC.2011-11-21Not applicableUs
ZidovudineSyrup50 mg/5mLOralCipla Ltd.2008-06-26Not applicableUs
ZidovudineCapsule100 mg/1OralAurobindo Pharma Limited2006-03-27Not applicableUs
ZidovudineTablet300 mg/1OralRoxane Laboratories, Inc2005-09-192016-10-13Us
ZidovudineTablet, film coated300 mg/1OralCitron Pharma LLC2005-09-19Not applicableUs
ZidovudineCapsule100 mg/1OralBoca Pharmacal, LLC2012-08-17Not applicableUs
ZidovudineTablet, film coated300 mg/1OralLucid Pharma Llc2005-09-19Not applicableUs
ZidovudineCapsule100 mg/1OralEdenbridge Pharmaceuticals, LLC2012-04-01Not applicableUs
ZidovudineTablet, film coated300 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
ZidovudineCapsule100 mg/1OralLucid Pharma Llc2006-03-27Not applicableUs
ZidovudineTablet, film coated300 mg/1OralMylan Pharmaceuticals Inc.2008-12-19Not applicableUs
ZidovudineCapsule100 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
ZidovudineTablet, film coated300 mg/1OralREMEDYREPACK INC.2012-01-172016-10-26Us
ZidovudineSolution50 mg/5mLOralBoca Pharmacal, LLC2012-08-17Not applicableUs
ZidovudineSyrup50 mg/5mLOralEdenbridge Pharmaceuticals, LLC2012-04-01Not applicableUs
ZidovudineTablet, film coated300 mg/1OralREMEDYREPACK INC.2015-05-19Not applicableUs
ZidovudineTablet, film coated300 mg/1OralCipla Ltd.2010-10-27Not applicableUs
ZidovudineTablet, film coated300 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
ZidovudineTablet, film coated300 mg/1OralAmerican Health Packaging2011-01-03Not applicableUs
ZidovudineTablet300 mg/1OralREMEDYREPACK INC.2016-11-08Not applicableUs
ZidovudineTablet, film coated300 mg/1OralAurobindo Pharma Limited2005-09-19Not applicableUs
ZidovudineTablet, film coated300 mg/1OralLannett Company, Inc.2014-03-25Not applicableUs
ZidovudineCapsule100 mg/1OralCipla Ltd.2007-05-23Not applicableUs
ZidovudineTablet, film coated300 mg/1Oralbryant ranch prepack2005-09-19Not applicableUs
ZidovudineTablet, film coated300 mg/1OralA S Medication Solutions2014-03-25Not applicableUs
ZidovudineTablet300 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
ZidovudineSyrup10 mg/mLOralAurobindo Pharma Limited2005-09-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Abacavir Sulfate, Lamivudine and ZidovudineLupin Pharmaceuticals, Inc.
Apo-abacavir-lamivudine-zidovudineApotex Inc
Apo-lamivudine-zidovudineApotex Inc
Apo-zidovudine-lamivudine-nevirapineApotex Inc
Auro-lamivudine/zidovudineAuro Pharma Inc
CombivirStat Rx USA
Lamivudine and ZidovudineTeva Pharmaceuticals USA Inc
Lamivudine ZidovudineDIRECT RX
Teva-lamivudine/zidovudineTeva Canada Limited
TrizivirState of Florida DOH Central Pharmacy
SaltsNot Available
Categories
UNII4B9XT59T7S
CAS number30516-87-1
WeightAverage: 267.2413
Monoisotopic: 267.096753929
Chemical FormulaC10H13N5O4
InChI KeyHBOMLICNUCNMMY-XLPZGREQSA-N
InChI
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
IUPAC Name
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
CC1=CN([[email protected]]2C[[email protected]](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Pharmacology
IndicationUsed in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
Structured Indications
PharmacodynamicsZidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.
Mechanism of actionZidovudine, a structural analog of thymidine, is a prodrug that must be phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). It inhibits the activity of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. It competes with the natural substrate dGTP and incorporates itself into viral DNA. It is also a weak inhibitor of cellular DNA polymerase α and γ.
TargetKindPharmacological actionActionsOrganismUniProt ID
Reverse transcriptase/RNaseHProteinyes
inhibitor
Human immunodeficiency virus 1Q72547 details
Telomerase reverse transcriptaseProteinunknown
inhibitor
HumanO14746 details
Related Articles
AbsorptionRapid and nearly complete absorption from the gastrointestinal tract following oral administration; however, because of first-pass metabolism, systemic bioavailability of zidovudine capsules and solution is approximately 65% (range, 52 to 75%). Bioavailability in neonates up to 14 days of age is approximately 89%, and it decreases to approximately 61% and 65% in neonates over 14 days of age and children 3 months to 12 years, respectively. Administration with a high-fat meal may decrease the rate and extent of absorption.
Volume of distribution

Apparent volume of distribution, HIV-infected patients, IV administration = 1.6 ± 0.6 L/kg

Protein binding30-38%
Metabolism

Hepatic. Metabolized by glucuronide conjugation to major, inactive metabolite, 3′-azido-3′-deoxy-5′- O-beta-D-glucopyranuronosylthymidine (GZDV). UGT2B7 is the primary UGT isoform that is responsible for glucuronidation. Compared to zidovudine, GZDV's area under the curve is approximately 3-fold greater. The cytochrome P450 isozymes are responsible for the reduction of the azido moiety to form 3'-amino-3'- deoxythymidine (AMT).

SubstrateEnzymesProduct
Zidovudine
Not Available
3'-azido-3'-deoxy-5'- O-beta-D-glucopyranuronosylthymidineDetails
Zidovudine
Not Available
3’-amino-3’-deoxythimidineDetails
Zidovudine
Not Available
3’-amino-3’-deoxythimidine glucuronideDetails
Zidovudine
Not Available
5’glucuronyl zidovudineDetails
Route of eliminationAs in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged and about 45% of the dose was excreted as GZDV.
Half lifeElimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)
Clearance
  • 0.65 +/- 0.29 L/hr/kg [HIV-infected, Birth to 14 Days of Age]
  • 1.14 +/- 0.24 L/hr/kg [HIV-infected, 14 Days to 3 Months of Age]
  • 1.85 +/- 0.47 L/hr/kg [HIV-infected, 3 Months to 12 Years of Age].
    The transporters, ABCB1, ABCC4, ABCC5, and ABCG2 are involved with the clearance of zidovudine.
ToxicitySymptoms of overdose include fatigue, headache, nausea, and vomiting. LD50 is 3084 mg/kg (orally in mice).
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategorySMPDB ID
Zidovudine Action PathwayDrug actionSMP00747
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Zidovudine can be decreased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Zidovudine can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Zidovudine can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Zidovudine can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Zidovudine can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Zidovudine can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Zidovudine can be increased when it is combined with Albendazole.Approved, Vet Approved
Albumin-interferon alphaThe risk or severity of adverse effects can be increased when Albumin-interferon alpha is combined with Zidovudine.Investigational
AldosteroneThe serum concentration of Zidovudine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Zidovudine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Zidovudine can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinThe serum concentration of Zidovudine can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Zidovudine can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
AmantadineThe serum concentration of Zidovudine can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Zidovudine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Zidovudine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Zidovudine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Zidovudine can be increased when it is combined with Amlodipine.Approved
AmodiaquineZidovudine may increase the neutropenic activities of Amodiaquine.Approved
AmprenavirThe serum concentration of Zidovudine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Zidovudine can be increased when it is combined with Amsacrine.Approved
Antithrombin III humanThe serum concentration of Zidovudine can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Zidovudine can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Zidovudine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Zidovudine can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Zidovudine can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Zidovudine can be decreased when combined with Armodafinil.Approved, Investigational
AstemizoleThe serum concentration of Zidovudine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Zidovudine can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Zidovudine can be decreased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Zidovudine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Zidovudine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Zidovudine can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Zidovudine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Zidovudine can be increased when it is combined with Azithromycin.Approved
BatimastatThe serum concentration of Zidovudine can be decreased when it is combined with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Zidovudine.Investigational
BenazeprilThe serum concentration of Zidovudine can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Zidovudine can be decreased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Zidovudine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Zidovudine can be increased when it is combined with Bepridil.Approved, Withdrawn
BexaroteneThe serum concentration of Zidovudine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Zidovudine can be decreased when it is combined with Bi201335.Investigational
BiperidenThe serum concentration of Zidovudine can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Zidovudine can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Zidovudine can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Zidovudine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zidovudine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Zidovudine can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Zidovudine can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Zidovudine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Zidovudine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Zidovudine can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Zidovudine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Zidovudine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Zidovudine can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Zidovudine can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Zidovudine can be decreased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Zidovudine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Zidovudine can be decreased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Zidovudine can be increased when combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Zidovudine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Zidovudine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Zidovudine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Zidovudine can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Zidovudine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Zidovudine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Zidovudine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Zidovudine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Zidovudine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Zidovudine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Zidovudine can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Zidovudine can be decreased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Zidovudine can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Zidovudine can be decreased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Zidovudine can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Zidovudine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Zidovudine can be increased when it is combined with Citalopram.Approved
ClarithromycinClarithromycin may increase the myelosuppressive activities of Zidovudine.Approved
ClemastineThe metabolism of Zidovudine can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Zidovudine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Zidovudine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Zidovudine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Zidovudine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clozapine.Approved
CobicistatThe metabolism of Zidovudine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Zidovudine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Zidovudine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Zidovudine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Zidovudine can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Zidovudine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Zidovudine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Zidovudine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Zidovudine can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Zidovudine can be decreased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Zidovudine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Zidovudine can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Zidovudine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Zidovudine can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Zidovudine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Zidovudine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Zidovudine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zidovudine.Approved
DextromethorphanThe serum concentration of Zidovudine can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Zidovudine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Zidovudine can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Zidovudine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Zidovudine can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Zidovudine can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Zidovudine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Zidovudine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Zidovudine.Approved, Investigational
DoxorubicinThe serum concentration of Zidovudine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Zidovudine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Zidovudine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Zidovudine can be decreased when combined with Dronedarone.Approved
EcabetThe serum concentration of Zidovudine can be decreased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Zidovudine can be decreased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Zidovudine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Zidovudine can be decreased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Zidovudine can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Zidovudine can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Zidovudine can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Zidovudine can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Zidovudine can be decreased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Zidovudine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Zidovudine can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Zidovudine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Zidovudine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Zidovudine can be decreased when combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Zidovudine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Zidovudine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Zidovudine can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Zidovudine can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Zidovudine can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Zidovudine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Zidovudine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Zidovudine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Zidovudine can be increased when it is combined with Fidaxomicin.Approved
FloxuridineThe metabolism of Zidovudine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Zidovudine can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Zidovudine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Zidovudine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Zidovudine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Zidovudine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Zidovudine can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe metabolism of Zidovudine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Zidovudine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Zidovudine can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zidovudine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Zidovudine can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Zidovudine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Zidovudine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Zidovudine can be decreased when it is combined with Gabexate.Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Zidovudine.Approved, Investigational
GefitinibThe serum concentration of Zidovudine can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe serum concentration of Zidovudine can be decreased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Zidovudine can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Zidovudine can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Zidovudine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Zidovudine can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Zidovudine can be decreased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Zidovudine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Zidovudine can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Zidovudine can be increased when it is combined with Haloperidol.Approved
HirulogThe serum concentration of Zidovudine can be decreased when it is combined with Hirulog.Experimental
HydrocortisoneThe serum concentration of Zidovudine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Zidovudine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Zidovudine can be decreased when it is combined with idraparinux.Investigational
IFNaThe risk or severity of adverse effects can be increased when IFNa is combined with Zidovudine.Investigational
ImatinibThe metabolism of Zidovudine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Zidovudine can be decreased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Zidovudine can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Zidovudine can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Zidovudine can be increased when it is combined with Indomethacin.Approved, Investigational
Interferon Alfa-2a, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.Approved
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Zidovudine.Approved
Interferon alfa-n1The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.Approved
Interferon beta-1aThe risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.Approved
Interferon gamma-1bThe risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.Approved, Investigational
IrbesartanThe metabolism of Zidovudine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Zidovudine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Zidovudine can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Zidovudine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Zidovudine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Zidovudine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zidovudine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Zidovudine can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe serum concentration of Zidovudine can be decreased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Zidovudine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Zidovudine can be decreased when combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Zidovudine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Zidovudine can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Zidovudine can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe serum concentration of Zidovudine can be decreased when it is combined with Lepirudin.Approved
LevofloxacinThe serum concentration of Zidovudine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Zidovudine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Zidovudine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Zidovudine can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe serum concentration of Zidovudine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Zidovudine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Zidovudine can be decreased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Zidovudine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Zidovudine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Zidovudine can be decreased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Zidovudine can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Zidovudine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Zidovudine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Zidovudine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zidovudine can be increased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Zidovudine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Zidovudine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Zidovudine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Zidovudine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Zidovudine can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zidovudine.Withdrawn
MethadoneThe serum concentration of Zidovudine can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Zidovudine can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Zidovudine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Zidovudine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Zidovudine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Zidovudine can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Zidovudine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Zidovudine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Zidovudine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Zidovudine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Zidovudine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Zidovudine can be decreased when it is combined with Moexipril.Approved
MorphineThe serum concentration of Zidovudine can be increased when it is combined with Morphine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Zidovudine can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Zidovudine can be decreased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Zidovudine can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Zidovudine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Zidovudine can be increased when it is combined with Naringenin.Experimental
Natural alpha interferonThe risk or severity of adverse effects can be increased when Natural alpha interferon is combined with Zidovudine.Approved, Investigational
NCX 4016The serum concentration of Zidovudine can be decreased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Zidovudine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Zidovudine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Zidovudine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Zidovudine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Zidovudine can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Zidovudine can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Zidovudine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Zidovudine can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Zidovudine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Zidovudine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Zidovudine can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Zidovudine can be decreased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Zidovudine can be decreased when it is combined with Norethisterone.Approved
OlaparibThe metabolism of Zidovudine can be decreased when combined with Olaparib.Approved
OmapatrilatThe serum concentration of Zidovudine can be decreased when it is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Zidovudine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Zidovudine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Zidovudine can be decreased when it is combined with Otamixaban.Investigational
P-NitrophenolThe serum concentration of Zidovudine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Zidovudine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Zidovudine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Zidovudine can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Zidovudine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Zidovudine can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.Approved
Peginterferon beta-1aThe risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Zidovudine.Approved
PentobarbitalThe metabolism of Zidovudine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Zidovudine can be decreased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Zidovudine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Zidovudine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Zidovudine can be decreased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Zidovudine can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Zidovudine can be decreased when combined with Pioglitazone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Zidovudine can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Zidovudine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Zidovudine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Zidovudine can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Zidovudine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Zidovudine can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Zidovudine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Zidovudine can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe metabolism of Zidovudine can be decreased when combined with Probenecid.Approved
ProgesteroneThe serum concentration of Zidovudine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Zidovudine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Zidovudine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Zidovudine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Zidovudine can be increased when it is combined with Protriptyline.Approved
PyrimethamineThe metabolism of Zidovudine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Zidovudine can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Zidovudine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Zidovudine can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Zidovudine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Zidovudine can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Zidovudine can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Zidovudine can be decreased when it is combined with Racecadotril.Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Zidovudine.Approved
RamiprilThe serum concentration of Zidovudine can be decreased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Zidovudine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Zidovudine can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Zidovudine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Zidovudine can be increased when it is combined with Regorafenib.Approved
RemikirenThe serum concentration of Zidovudine can be decreased when it is combined with Remikiren.Approved
ReserpineThe serum concentration of Zidovudine can be decreased when it is combined with Reserpine.Approved
RibavirinThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ribavirin.Approved
RifabutinThe serum concentration of Zidovudine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Zidovudine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Zidovudine can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Zidovudine can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Zidovudine can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Zidovudine can be decreased when it is combined with Rivaroxaban.Approved
RolapitantThe serum concentration of Zidovudine can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe metabolism of Zidovudine can be decreased when combined with Rosiglitazone.Approved, Investigational
SaquinavirThe serum concentration of Zidovudine can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Zidovudine can be decreased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Zidovudine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Zidovudine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Zidovudine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Zidovudine can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Zidovudine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zidovudine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Zidovudine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Zidovudine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Zidovudine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Zidovudine can be decreased when it is combined with Sitagliptin.Approved, Investigational
SorafenibThe serum concentration of Zidovudine can be increased when it is combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Zidovudine can be decreased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Zidovudine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Zidovudine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Zidovudine can be increased when it is combined with Staurosporine.Experimental
StavudineThe therapeutic efficacy of Stavudine can be decreased when used in combination with Zidovudine.Approved, Investigational
StiripentolThe serum concentration of Zidovudine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Zidovudine can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Zidovudine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Zidovudine can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Zidovudine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Zidovudine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Zidovudine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Zidovudine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Zidovudine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Zidovudine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Zidovudine can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Zidovudine can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Zidovudine can be decreased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Zidovudine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Zidovudine can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe serum concentration of Zidovudine can be decreased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Zidovudine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Zidovudine can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Zidovudine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Zidovudine can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Zidovudine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Zidovudine can be increased when it is combined with Testosterone.Approved, Investigational
ThiorphanThe serum concentration of Zidovudine can be decreased when it is combined with Thiorphan.Experimental
TicagrelorThe serum concentration of Zidovudine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Zidovudine can be decreased when combined with Ticlopidine.Approved
TipranavirThe serum concentration of Zidovudine can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Zidovudine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Zidovudine can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Zidovudine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe metabolism of Zidovudine can be decreased when combined with Topiramate.Approved
TrandolaprilThe serum concentration of Zidovudine can be decreased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Zidovudine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe serum concentration of Zidovudine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Zidovudine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Zidovudine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Zidovudine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Zidovudine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Zidovudine can be increased when it is combined with Troleandomycin.Approved
UbenimexThe serum concentration of Zidovudine can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Zidovudine can be decreased when it is combined with Ulinastatin.Investigational
ValaciclovirValaciclovir may increase the central nervous system depressant (CNS depressant) activities of Zidovudine.Approved, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Valganciclovir is combined with Zidovudine.Approved, Investigational
Valproic AcidThe serum concentration of Zidovudine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Zidovudine can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Zidovudine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Zidovudine can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Zidovudine can be decreased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Zidovudine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Zidovudine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Zidovudine can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Zidovudine can be decreased when combined with Voriconazole.Approved, Investigational
XimelagatranThe serum concentration of Zidovudine can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Zidovudine can be decreased when it is combined with Ym150.Investigational
ZafirlukastThe metabolism of Zidovudine can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Zidovudine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Zidovudine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. De Clercq E: HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155-69. [PubMed:7508227 ]
  2. Yarchoan R, Mitsuya H, Broder S: AIDS therapies. Sci Am. 1988 Oct;259(4):110-9. [PubMed:3072667 ]
  3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173-80. [PubMed:7935654 ]
  4. Mitsuya H, Yarchoan R, Broder S: Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533-44. [PubMed:1699273 ]
  5. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100. [PubMed:2413459 ]
  6. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. [PubMed:12920168 ]
External Links
ATC CodesJ05AR01J05AR05J05AF01J05AR04
AHFS Codes
  • 08:18.08.20
PDB EntriesNot Available
FDA labelDownload (217 KB)
MSDSDownload (57.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9343
Blood Brain Barrier+0.6224
Caco-2 permeable-0.8728
P-glycoprotein substrateNon-substrate0.6959
P-glycoprotein inhibitor INon-inhibitor0.9118
P-glycoprotein inhibitor IINon-inhibitor0.8981
Renal organic cation transporterNon-inhibitor0.8798
CYP450 2C9 substrateNon-substrate0.663
CYP450 2D6 substrateNon-substrate0.8987
CYP450 3A4 substrateSubstrate0.5329
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.9143
CYP450 2D6 inhibitorNon-inhibitor0.9315
CYP450 2C19 inhibitorNon-inhibitor0.9175
CYP450 3A4 inhibitorNon-inhibitor0.848
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9585
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7484
BiodegradationReady biodegradable0.5673
Rat acute toxicity2.0464 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7124
hERG inhibition (predictor II)Non-inhibitor0.8821
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Viiv healthcare co
  • Aurobindo pharma ltd inc
  • Cipla ltd
  • Pharmaforce inc
  • Aurobindo pharma ltd
  • Hetero drugs ltd unit iii
  • Matrix laboratories ltd
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Tablet, film coatedOral150 mg/1
Injection, solutionIntravenous10 mg/mL
CapsuleOral100 mg
LiquidIntravenous10 mg
SyrupOral50 mg
TabletOral300 mg
CapsuleOral100 mg/1
SolutionOral50 mg/5mL
SyrupOral10 mg/mL
SyrupOral50 mg/5mL
TabletOral300 mg/1
Tablet, film coatedOral300 mg/1
Prices
Unit descriptionCostUnit
Retrovir 50 mg/5ml Syrup 240ml Bottle74.11USD bottle
Retrovir 300 mg tablet9.1USD tablet
Zidovudine 300 mg tablet6.17USD tablet
Retrovir 100 mg capsule3.09USD capsule
Retrovir iv infusion vial1.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2105487 No2002-09-242012-03-05Canada
CA2216634 No2004-07-202016-03-28Canada
US5905082 Yes1996-11-182016-11-18Us
US6294540 Yes1998-11-142018-11-14Us
US6417191 Yes1996-09-282016-09-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point113-115 °CPhysProp
water solubility2.01E+004 mg/L (at 25 °C)PHYSICIANS DESK REFERENCE (2003)
logP0.05HANSCH,C ET AL. (1995)
Caco2 permeability-5.16ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility16.3 mg/mLALOGPS
logP-0.1ALOGPS
logP-0.3ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area108.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity61.7 m3·mol-1ChemAxon
Polarizability24.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPyrimidine nucleosides
Sub ClassNot Available
Direct ParentPyrimidine nucleosides
Alternative Parents
Substituents
  • Pyrimidine nucleoside
  • Pyrimidone
  • Pyrimidine
  • Hydropyrimidine
  • Saccharide
  • Heteroaromatic compound
  • Vinylogous amide
  • Oxolane
  • Urea
  • Lactam
  • Azo imide
  • Azo compound
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organic salt
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72547
Molecular Weight:
65223.615 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209. [PubMed:9084959 ]
  3. De Clercq E: Antiretroviral drugs. Curr Opin Pharmacol. 2010 Oct;10(5):507-15. doi: 10.1016/j.coph.2010.04.011. Epub 2010 May 12. [PubMed:20471318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Trna binding
Specific Function:
Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chro...
Gene Name:
TERT
Uniprot ID:
O14746
Molecular Weight:
126995.435 Da
References
  1. Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, Smit de V, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR: Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. doi: 10.1093/infdis/jit006. Epub 2013 Jan 9. [PubMed:23303810 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798 ]
  3. Authors unspecified: Letter: Exercise testing and coronary heart disease. N Engl J Med. 1975 Dec 4;293(23):1208-10. [PubMed:1186798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
TK1
Uniprot ID:
P04183
Molecular Weight:
25468.455 Da
References
  1. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al.: Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7. [PubMed:2430286 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. [PubMed:12920168 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Quevedo MA, Moroni GN, Brinon MC: Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem Biophys Res Commun. 2001 Nov 9;288(4):954-60. [PubMed:11689002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Worner P, Brossmer R: Platelet aggregation and the release induced by inophores for divalent cations. Thromb Res. 1975 Apr;6(4):295-305. [PubMed:1094583 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function:
Sodium-dependent and pyrimidine-selective. Exhibits the transport characteristics of the nucleoside transport system cit or N2 subtype (N2/cit) (selective for pyrimidine nucleosides and adenosine). It also transports the antiviral pyrimidine nucleoside analogs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC). It may be involved in the intestinal absorption and renal handling of ...
Gene Name:
SLC28A1
Uniprot ID:
O00337
Molecular Weight:
71583.18 Da
References
  1. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, Pastor-Anglada M: Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther. 2004 Dec;9(6):993-1002. [PubMed:15651758 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.
Gene Name:
SLC29A2
Uniprot ID:
Q14542
Molecular Weight:
50112.335 Da
References
  1. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD: Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 2001 Apr-Jun;18(2):161-7. [PubMed:11463208 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9. [PubMed:16791115 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL: The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008 Jun;325(3):859-68. doi: 10.1124/jpet.108.136523. Epub 2008 Mar 25. [PubMed:18364470 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, Dormont D, Clayette P: ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28. [PubMed:15456083 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Pan G, Giri N, Elmquist WF: Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos. 2007 Jul;35(7):1165-73. Epub 2007 Apr 16. [PubMed:17437964 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58